Higher healthcare cost and utilization before and after diagnosis of AATD in the United States.

ABSTRACT:

Purpose

Patients with alpha-1 antitrypsin deficiency (AATD) often experience substantial delays from the onset of symptoms to a diagnosis. We explored the impact of delayed diagnosis of AATD on healthcare costs and utilization by assessing costs/utilization before and after diagnosis.

Methods

Retrospective claims data was used to conduct a longitudinal analysis of a cohort of patients with follow-up over four years in a commercial claims database was conducted. Patients with at least four years of claims experience between the years 2011 - 2017 were included in this study. Outcome measures were calculated for each year (Year 1 pre-index diagnosis, and Years 1, 2, and 3 post-index follow-up). Measures included healthcare costs (pharmacy and medical costs), medical costs, inpa

SUBMITTER: Blanchette CM 

PROVIDER: S-EPMC11568589 | biostudies-literature | 2024 Nov

REPOSITORIES: biostudies-literature